Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MicrSoy-20
- Development stage
- Phase 2
- Modality
- Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
MicrSoy-20 (MS-20) is a fermented soybean extract developed as a chemotherapeutical adjuvant. It has been studied for its ability to reduce chemotherapy-associated fatigue and appetite loss in cancer patients. Clinical studies suggest that MS-20 can help restore chemotherapy-induced immunosuppression and improve quality of life by enhancing physical and social functioning during cancer treatment. The mechanism appears to involve modulation of immune parameters, though the precise molecular targets are not fully defined[4].
- Brand names
- MicrSoy-20MicrSoy20MicrSoy 20MicrSoy
- Other names
- fermented soybean extractMS-20MS20MS 20
Beyond the preview
Go deeper on MicrSoy-20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicrSoy-20.